A novel anti-CD47 antibody with therapeutic potential for NK/T-cell lymphoma
Open Access
- 30 September 2024
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 20 (1) , 2408088
Abstract
NK/T-cell lymphoma (NKTCL) is a rare type of non-Hodgkin lymphoma (NHL). Although L-asparaginase-based chemotherapy has significantly improved survival in early-stage patients, the prognosis is poor in advanced and relapsed or refractory patients. CD47 is a promising target for cancer immunotherapy. However, the expression of CD47 in NKTCL and the antitumor effect and mechanism of the anti-CD47 monoclonal antibody (mAb) AK117 in NKTCL remain unclear. Firstly, the expression level of CD47 protein in NKTCL cells was detected by immunoblot and flow cytometry. Secondly, in order to validate the role of CD47 downregulation in the proliferation, apoptosis, and cell cycle of NKTCL cells, we used shRNA transfection to knock down CD47 expression. We determined the effect of knocking down CD47 and the novel anti-CD47 antibody AK117 on the phagocytosis of NKYS and YTS cells by M2 macrophages in vitro. Finally, we assessed the ability of AK117 to inhibit tumor growth in an NKTCL xenograft model in which YTS cells were engrafted in SCID mice. The results showed that CD47 is relatively highly expressed in NKTCL cells. CD47 knockdown in NKTCL promoted phagocytosis by M2 macrophages in an in vitro coculture assay. The study also demonstrated that anti-CD47 mAb AK117 promoted phagocytosis of NKTCL cells by M2 macrophages. In addition, in vivo experiments showed that the anti-CD47 mAb AK117 significantly inhibited the growth of subcutaneous xenograft tumors in SCID mice compared to the control antibody IgG. Our results indicate that targeting CD47 monoclonal antibodies is a potential therapeutic strategy for NKTCL.Keywords
Funding Information
- Hunan Provincial Natural Science Foundation of China (2021JJ30425, 2022JJ30789, 2022JJ30026)
- National Natural Science Foundation of China (82204414)
- Natural Science Foundation of Hunan Province
This publication has 41 references indexed in Scilit:
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem CellsCell, 2009
- Humanized mice in translational biomedical researchNature Reviews Immunology, 2007
- Immune resistance orchestrated by the tumor microenvironmentImmunological Reviews, 2006
- The SIRP family of receptors and immune regulationNature Reviews Immunology, 2006
- Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed antitumor potency for multiple myelomaLeukemia Research, 2005
- Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytesTrends in Immunology, 2002
- Integrin-associated protein (CD47) and its ligandsTrends in Cell Biology, 2001
- CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemiaNature Medicine, 1999
- In vivo expression of alternatively spliced forms of integrin-associated protein (cd47)Journal of Cell Science, 1995
- Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins.Journal of Cell Biology, 1990